Search Within

Michael Morris

  1. "Lancet Oncology"
Formats
  1. Journal Article (4)
  2. Review (1)
Groups
  1. Department of Medicine (5)
  2. Genitourinary Oncology Service (5)
  3. Solid Tumor Oncology Division (5)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  5. Biostatistics Service (1)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (1)

More Groups

People
  1. Adam Kesner (1)
  2. Assen Kirov (1)
  3. Audrey Mauguen (1)
  4. Charles Rudin (1)
  5. Heiko Schoder (1)
  6. Jason Lewis (1)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2023 (1)
  4. 2013 (1)
Publications
  1. Lancet Oncology (5)
Publishers
  1. Elsevier Science, Inc. (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): An open-label, randomised, phase 3 trial
    Journal Article

    Fizazi, K.; Morris, M. J.; Shore, N.; Chi, K. N.; Crosby, M.; de Bono, J. S.; Herrmann, K.; Roubaud, G.; Nagarajah, J.; Fleming, M.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Defining the role of pragmatic clinical trials in cancer clinical research: Outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
    Review

    Cardoso Borges, F.; van der Graaf, W. T. A.; Saesen, R.; Aebi, S.; Amariutei, A. E.; Bekelman, J.; Gorlia, T.; Hulstaert, F.; Huys, I.; Kluetz, P.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial
    Journal Article

    Tendler, S.; Dunphy, M. P.; Agee, M.; O'Donoghue, J.; Aly, R. G.; Choudhury, N. J.; Kesner, A.; Kirov, A.; Mauguen, A.; Baine, M. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open-label, randomised, phase 3 trial
    Journal Article

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial
    Journal Article

    Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save